Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Shared REMS For Transmucosal Fentanyls Could Expand Market For Meda’s Onsolis As It Exits More Restrictive Program

This article was originally published in The Pink Sheet Daily

Executive Summary

Class-wide Risk Evaluation and Mitigation Strategy for transmucosal immediate-release fentanyl products will begin operations in March 2012, with participants in REMS for individual products to be transitioned automatically to the new system.

You may also be interested in...



Keeping Track: Neurology And Pain Products Keep FDA Occupied

The latest drug development news and highlights from our FDA Performance Tracker.

Stairway To Heaven: REMS Website Integrated With Health Care Systems

Participants in a two-day FDA meeting on REMS standardization and assessment suggested a website containing all REMS information and enrollment functions and allowing interaction with existing health records and claims systems would facilitate compliance with safety requirements.

Lotronex REMS’ Verification Process Should Be Electronic, FDA Panel Says

Drug Safety and Risk Management Advisory Committee overwhelmingly favors elimination of paper-based sticker system to verify prescriber enrollment and documentation of safe use conditions under Prometheus’ REMS for the irritable bowel syndrome drug.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS073207

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel